Analyzing MicroRNAs and Vitamin B12 in Long COVID Patients with Neurological Symptoms
Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19
This study is testing if changes in certain microRNAs and vitamin B12 levels in the blood can help understand and treat neurological symptoms like depression and fatigue in people who have long COVID.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Instituto Nacional de Rehabilitacion Government |
| Locations | 1 site (Mexico City, Mexico City) |
| Trial ID | NCT06864156 on ClinicalTrials.gov |
What this trial studies
This study evaluates the expression of specific microRNAs and vitamin B12 levels in individuals experiencing neurological symptoms such as depression, anxiety, and fatigue following COVID-19 infection. By analyzing blood samples from these patients, the research aims to identify changes in biological processes that occur post-infection. The ultimate goal is to enhance diagnostic methods and develop targeted therapies for long COVID symptoms. The study focuses on patients who have had confirmed COVID-19 and exhibit these neurological symptoms three months after their acute infection.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed COVID-19 diagnosis who are experiencing neurological symptoms of depression, anxiety, and fatigue at least three months post-infection.
Not a fit: Patients who have had recent acute COVID-19 symptoms or pre-existing neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and therapies for patients suffering from long COVID-related neurological symptoms.
How similar studies have performed: While the specific approach of analyzing microRNAs and vitamin B12 in long COVID is relatively novel, similar studies have explored biomarkers in post-viral syndromes with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing. * With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms. Exclusion Criteria: * Subjects who have presented symptoms of acute infection in the last twelve weeks. * Subjects who present diagnostic premorbid neurological alterations. * Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.
Where this trial is running
Mexico City, Mexico City
- Instituto Nacional de Rehabilitación — Mexico City, Mexico City, Mexico (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.